News

vasopharm GmbH today announced the appointment of Prof Dr John F. Stover as Chief Medical Officer.

vasopharm GmbH is pleased to announce today that the Last Patient Last Visit (LPLV) in its phase 3 NOSTRA III clinical trial occurred on June 17, 2020

vasopharm GmbH is pleased to announce that enrolment into the pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial is completed. vasopharm remains on track to deliver headline data by end of 2020.

vasopharm GmbH, a privately held biopharmaceutical company, today announced that following a safety and efficacy interim assessment conducted according to the clinical trial protocol by the Data Monitoring Committee (DMC) it has received the following recommendation:

50% of patients enrolled in trial triggers interim data review. vasopharm GmbH today announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, regrets to announce that Dr Irina Antonijevic (CMO) will return to Boston as a result of a family health issue.